Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/aging-biomarkers.md — the filesystem corpus, unchanged. Not an edit.
11.4 kB
Revision 1
Revision 2
lines 6–13 → 6–135 unchanged lines not shown
horizon: "late 2020s"horizon: "late 2020s"categories: ["longevity"]categories: ["longevity"]tags: ["biomarkers", "aging", "clinical trials", "regulation", "measurement"]tags: ["biomarkers", "aging", "clinical trials", "regulation", "measurement"]summary: "Measurable indicators intended to track the rate or extent of biological aging, sought as surrogate endpoints so that anti-aging trials can read out in years rather than decades."summary: "Measurable indicators meant to track the rate or extent of biological aging, sought as surrogate endpoints so that anti-aging trials can read out in years rather than decades."updated: "2026-07-27"updated: "2026-10-29"issues: ["No source for the claim that no aging biomarker has passed FDA biomarker qualification.", "Proteomic and metabolomic panels are named as candidate classes without any citation."]issues: ["No source for the claim that no aging biomarker has passed FDA biomarker qualification.", "Proteomic and metabolomic panels are named as candidate classes without any citation."]------ lines 25–31 → 25–3511 unchanged lines not shown
}}`````` **Aging biomarkers** are measurable quantities intended to indicate how far or how fast a person is aging, independent of the calendar. The field wants them for a specific and practical reason: without one, a trial testing whether a drug slows aging must wait for participants to become ill or die, which takes decades and enormous numbers of people. A validated biomarker would compress that to a few years. None has been accepted for the purpose.**Aging biomarkers** are measurable quantities intended to indicate how far or how fast a person isaging, independent of the calendar. The field wants them for a practical reason. Without one, atrial testing whether a drug slows aging must wait for participants to become ill or die, whichtakes decades and very large numbers of people; a validated biomarker would shorten that to a fewyears. None has been accepted for the purpose. ```keyfacts```keyfacts[[lines 37–88 → 41–1685 unchanged lines not shown
## Why the field needs one## Why the field needs one The [[geroscience-hypothesis]] holds that slowing aging would delay many chronic diseases at once. Testing it requires an endpoint. Lifespan is unambiguous and unusable in humans. Incidence of a single disease reintroduces the disease-by-disease framing the hypothesis was built to escape. A composite of several age-related diseases plus death is the compromise adopted by the [[metformin|TAME]] design, and it still requires thousands of participants over years.The [[geroscience-hypothesis]] holds that slowing aging would delay many chronic diseases at once,and testing it requires an endpoint. Lifespan is unambiguous but unusable in humans. The incidenceof a single disease brings back the disease-by-disease framing the hypothesis was built to escape.The [[metformin|TAME]] design adopts a compromise, a composite of several age-related diseases plusdeath, and it still needs thousands of participants followed over years. A surrogate biomarker would change the economics. A six-month readout would let sponsors run dose-ranging studies, compare candidate compounds, and fail fast, which is how drug development works in every field that has one. The absence of a surrogate is a substantial part of why so few geroprotector candidates have entered serious human testing despite a large animal literature.A surrogate biomarker would change the economics. With a six-month readout, sponsors could rundose-ranging studies, compare candidate compounds and abandon failures early, as drug developers doin every field that has a surrogate. Its absence is a substantial part of the reason so fewgeroprotector candidates have entered serious human testing despite a large animal literature. ## What counts as a biomarker of aging## What counts as a biomarker of aging The criteria most often cited descend from work sponsored by the American Federation for Aging Research in the late 1980s and restated since.[^baker1988] A biomarker of aging should predict remaining lifespan or the onset of age-related dysfunction better than chronological age does; it should reflect an underlying process, ideally one of the [[hallmarks-of-aging]], rather than a specific disease; it should be measurable repeatedly without significant harm; and it should work in laboratory animals as well as in humans, so that it can be validated against lifespan in a species where lifespan is observable.The criteria most often cited descend from work sponsored by the American Federation for AgingResearch in the late 1980s and restated since.[^baker1988] A biomarker of aging should predictremaining lifespan or the onset of age-related dysfunction better than chronological age does. Itshould reflect an underlying process, ideally one of the [[hallmarks-of-aging]], rather than aspecific disease. It should be measurable repeatedly without significant harm, and it should work inlaboratory animals as well as in humans, so that it can be validated against lifespan in a specieswhere lifespan is observable. Modern framings add a decomposition into three tiers. Analytical validity asks whether the measurement is reproducible across laboratories, platforms and repeat draws. Clinical validity asks whether it predicts outcomes in independent cohorts. Responsiveness asks whether it moves when an intervention is applied, and, crucially, whether a change in the marker predicts a corresponding change in the outcome. Most candidates have some evidence for the first two tiers and almost none for the third.Modern framings split validation into three tiers. Analytical validity asks whether the measurementis reproducible across laboratories, platforms and repeat draws. Clinical validity asks whether itpredicts outcomes in independent cohorts. Responsiveness asks whether the marker moves when anintervention is applied and, more demanding still, whether a change in the marker predicts acorresponding change in the outcome. Most candidates have some evidence for the first two tiers andalmost none for the third. ## Candidate classes## Candidate classes Candidates are conventionally sorted by what they measure, a catalogue set out under [[biological-age]]. Sorted instead by which validity tier each class is stuck at, the picture is more useful, because the tier a class fails is what determines the experiment that would rescue it.Candidates are conventionally sorted by what they measure, a catalogue set out under[[biological-age]]. Sorting them instead by the validity tier at which each class is stuck is moreuseful, because the tier a class fails determines the experiment that would rescue it. **Molecular measures are cheap and hard to interpret.** DNA methylation dominates, in the form of [[epigenetic-clock|epigenetic clocks]], with proteomic, metabolomic, glycomic and transcriptomic panels alongside. One blood draw yields tens of thousands of features, and a model can be fitted from them to almost any outcome. That is simultaneously the attraction and the difficulty: an index selected for prediction carries no evidence that moving it moves anything, and that evidence cannot come from the data the index was fitted on.**Molecular measures are cheap and hard to interpret.** DNA methylation dominates, in the form of[[epigenetic-clock|epigenetic clocks]], with proteomic, metabolomic, glycomic and transcriptomicpanels alongside. One blood draw yields tens of thousands of features, and a model can be fittedfrom them to almost any outcome. That flexibility is both the attraction and the difficulty. Anindex selected for prediction carries no evidence that moving it moves anything, and that evidencecannot come from the data the index was fitted on. **Cellular measures are the ones the field most wants and least has.** Senescent-cell burden is the direct target of [[senolytics]], and no accepted method exists for quantifying it in a living person, because no clean marker of [[cellular-senescence]] exists to build the method on. Assays therefore rely on surrogates for a surrogate. Clonal haematopoiesis, a readout of [[stem-cell-exhaustion]], is the exception: measurable by sequencing, predictive of cardiovascular as well as blood outcomes, and confined to one tissue.**Cellular measures are the ones the field most wants and least has.** Senescent-cell burden is thedirect target of [[senolytics]], yet no accepted method exists for quantifying it in a livingperson, because there is no clean marker of [[cellular-senescence]] on which to build one. Assaystherefore rely on surrogates for a surrogate. Clonal haematopoiesis, a readout of[[stem-cell-exhaustion]], is the exception: it is measurable by sequencing and predictscardiovascular as well as blood outcomes, but it is confined to one tissue. **Immune and inflammatory measures track a real axis and move for the wrong reasons.** Composite immune-aging scores, thymic output measures and circulating markers linked to [[inflammaging]] all decline with age. They also shift within days after infection, injury or vaccination, which is close to disqualifying for something meant to read a decades-long process off a single timepoint.**Immune and inflammatory measures track a real axis and move for the wrong reasons.** Compositeimmune-aging scores, thymic output measures and circulating markers linked to [[inflammaging]] alldecline with age. They also shift within days after infection, injury or vaccination, which comesclose to disqualifying them as a way to read a decades-long process from a single timepoint. **Functional measures are the only class with real responsiveness data.** Gait speed, grip strength, chair-rise time and cardiorespiratory fitness predict mortality and disability well, and they already serve as endpoints in frailty and sarcopenia trials, so the regulatory path for them is partly mapped. The awkwardness is commercial rather than scientific: they improve reliably with training, so a sponsor whose drug is judged on grip strength is competing against [[exercise-and-aging|exercise]].**Functional measures are the only class with real responsiveness data.** Gait speed, grip strength,chair-rise time and cardiorespiratory fitness predict mortality and disability well. They alreadyserve as endpoints in frailty and sarcopenia trials, so their regulatory path is partly mapped. Theawkwardness is commercial rather than scientific: these measures improve reliably with training, soa sponsor whose drug is judged on grip strength is competing against[[exercise-and-aging|exercise]]. ## Coordination efforts## Coordination efforts The Biomarkers of Aging Consortium, established in the early 2020s, brought together academic groups, companies and funders to standardise definitions, share data and set validation criteria. Its output includes a framework paper setting out what would be required for a biomarker to be used in longevity-intervention trials and subsequent work on validation standards.[^moqri2023] The consortium's contribution is less a new measure than an agreed vocabulary and a shared benchmark, which the field previously lacked.The Biomarkers of Aging Consortium, established in the early 2020s, brought together academicgroups, companies and funders to standardise definitions, share data and set validation criteria.Its output includes a framework paper on what a biomarker would need before it could be used inlongevity-intervention trials, followed by work on validation standards.[^moqri2023] The consortiumhas contributed an agreed vocabulary and a shared benchmark, which the field previously lacked, morethan any new measure. > [!debate] Surrogates can mislead> [!debate] Surrogates can mislead> Cardiology provides the cautionary case. Antiarrhythmic drugs suppressed ventricular ectopic beats, a plausible surrogate for sudden cardiac death, and the Cardiac Arrhythmia Suppression Trial found they increased mortality.[^echt1991] A marker can be strongly associated with an outcome and still be the wrong thing to move.> Cardiology supplies the cautionary case. Antiarrhythmic drugs suppressed ventricular ectopic> beats, a plausible surrogate for sudden cardiac death, and the Cardiac Arrhythmia Suppression> Trial found that they increased mortality.[^echt1991] A marker can be strongly associated with an> outcome and still be the wrong thing to move. ## The regulatory bar## The regulatory bar Regulators do not accept surrogates because they correlate with outcomes. They require evidence that an intervention's effect on the surrogate accounts for its effect on the clinical outcome, which is a mediation claim and much harder to establish. In the United States, formal qualification runs through a biomarker qualification programme, and no aging biomarker has been submitted successfully through it.Regulators do not accept a surrogate because it correlates with outcomes. They require evidence thatan intervention's effect on the surrogate accounts for its effect on the clinical outcome, amediation claim that is much harder to establish. In the United States, formal qualification runsthrough a biomarker qualification programme, and no aging biomarker has been submitted successfullythrough it. A second obstacle is categorical. Aging is not recognised as an indication by the major regulators, so even a perfect biomarker would be measuring progress against something a label cannot name. This is why proposals in the field are usually framed around a specific age-related condition or around multimorbidity, and why the ICD classification of aging-related decline has been argued over with unusual intensity for a coding question. A working group convened around [[nir-barzilai|Nir Barzilai]]'s TAME trial published a shortlist of blood-based markers judged closest to usable for geroscience trials, chosen for availability and predictive validity rather than for mechanistic depth.[^justice2018] The economic case for clearing this obstacle is set out under [[longevity-dividend]].A second obstacle is categorical. The major regulators do not recognise aging as an indication, soeven a perfect biomarker would measure progress against something a label cannot name. Proposals inthe field are therefore usually framed around a specific age-related condition or aroundmultimorbidity, and the ICD classification of aging-related decline has been argued over withunusual intensity for a coding question. A working group convened around[[nir-barzilai|Nir Barzilai]]'s TAME trial published a shortlist of blood-based markers judgedclosest to usable in geroscience trials, chosen for availability and predictive validity rather thanfor mechanistic depth.[^justice2018] The economic case for clearing this obstacle is set out under[[longevity-dividend]]. ## Validation problems## Validation problems Validating a biomarker of aging against mortality is partly circular: mortality is the outcome, and a marker that predicts it may be measuring current illness rather than aging. Distinguishing the two requires long follow-up in healthy cohorts, which few datasets support.Validating a biomarker of aging against mortality is partly circular. Mortality is the outcome, anda marker that predicts it may be measuring current illness rather than aging. Telling the two apartrequires long follow-up in healthy cohorts, which few datasets support. Animal validation offers a partial escape. A marker that tracks lifespan across mouse strains and across interventions of known effect, including [[caloric-restriction]] and [[rapamycin]], has passed a test no human dataset can supply. Cross-species methylation clocks, which [[steve-horvath|Horvath]] and collaborators extended across mammalian species, were built partly for this purpose. The translation gap remains: a marker calibrated in mice may not carry the same meaning in a species that lives thirty times longer.Animal validation offers a partial way out. A marker that tracks lifespan across mouse strains andacross interventions of known effect, including [[caloric-restriction]] and [[rapamycin]], haspassed a test no human dataset can supply. Cross-species methylation clocks, which[[steve-horvath|Horvath]] and collaborators extended across mammalian species, were built partly forthis purpose. The translation gap remains, since a marker calibrated in mice may not carry the samemeaning in a species that lives thirty times longer. Reliability is the mundane problem that undermines many published intervention effects. Where a measure's test-retest variation is comparable to the effect being claimed, the claim cannot be evaluated, and this has been documented for several widely used clocks and partly remedied by reconstructing them on principal components.[^higgins2022] The same difficulty afflicted [[telomeres-and-telomerase|leukocyte telomere length]], the field's previous favourite marker, which proved too noisy at the individual level to be informative.Reliability is the mundane problem that undermines many published intervention effects. Where ameasure's test-retest variation is comparable to the effect being claimed, the claim cannot beevaluated. This has been documented for several widely used clocks and partly remedied byreconstructing them on principal components.[^higgins2022] The same difficulty afflicted[[telomeres-and-telomerase|leukocyte telomere length]], the field's previous favourite marker, whichproved too noisy at the individual level to be informative. ## Outlook## Outlook Two paths are open. One is to keep improving molecular measures until one clears the mediation bar, which will require intervention trials large enough to demonstrate that the marker carries the treatment effect. The other is to give up on surrogates for now and use function directly, which is the choice made by [[xprize-healthspan]] in defining its target as restored muscle, cognitive and immune performance. The second path is slower per trial and immune to the criticism that has attached to biological-age claims. Which route the field takes will shape whether the first credible human geroprotector result arrives from a biomarker readout or from a decade-long clinical endpoint.The field has two options. One is to keep improving molecular measures until one clears themediation bar, which will require intervention trials large enough to show that the marker carriesthe treatment effect. The other is to set surrogates aside for now and measure function directly,the choice [[xprize-healthspan]] made in defining its target as restored muscle, cognitive andimmune performance. The second path is slower per trial but immune to the criticism that hasattached to biological-age claims. The choice will help decide whether the first credible humangeroprotector result comes from a biomarker readout or from a decade-long clinical endpoint. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
84 lines are the same in both revisions, and 37 of them are not shown. Neither revision here is necessarily the current article — read Aging biomarkers for the text this wiki stands behind today.